Recent studies have revealed that radiomic signature was able to estimate the abundance of cluster of differentiation 8 (CD8) cells inside tumor, discriminate inflamed tumors from immune-desert tumors and predict response to anti-PD-1 and anti-PD-L1 immunotherapy (Sun et al. 2018). This evidence concerns the gene CD8A and neoplasm.